WallStSmart
ACHL

Achilles Therapeutics PLC ADR

NASDAQ: ACHL · HEALTHCARE · BIOTECHNOLOGY

$1.48
+0.00% today

Updated 2026-11-06

Market cap
$63.22M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.66
Dividend yield
—
52W range
$0 – $0
Volume
1.2M

Achilles Therapeutics PLC ADR (ACHL) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201820192020202120222023
Operating cash flow$-7598.00$-14.14M$-25.25M$-59.28M$-59.53M$-48.45M
Capital expenditures$258.00$942000.00$11.85M$7.63M$7.51M$1.10M
Depreciation——————
Stock-based comp$76.00$719000.00$2.99M$6.32M$7.02M$6.36M
Free cash flow$-7856.00$-15.08M$-37.10M$-66.92M$-67.05M$-49.55M
Investing cash flow——————
Financing cash flow——————
Dividends paid——————
Share repurchases——————
Debt repayment——————
Net change in cash——————

Frequently asked questions

How much free cash flow does ACHL generate?

ACHL produced $-49.55M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ACHL's balance sheet healthy?

ACHL holds $131.54M in cash and equivalents against — in long-term debt, on $142.37M of shareholder equity. That debt is best read against the cash flow the business throws off each year.